ערך בספרים למניה: CytoMed Therapeutics Ltd (GDTC)

Diversification of cell programs for tumor combat reduces risks, as confirmed by the book value per share of CytoMed Therapeutics (GDTC), which currently stands at 0.32. Collaboration with clinics advances personalized therapy for the gut and liver. The creation of affordable allogeneic CAR-T products ensures a technological breakthrough. Current indicator dynamics demonstrate the development vector of equity between reporting periods.

Singaporean cell therapy developer CytoMed Therapeutics (GDTC) operates amidst Asia's regulatory fragmentation, making the company's tangible asset base critical to its survival. When analyzing the projected book value per share, an investor assesses the residual value of net assets divided by the number of shares to determine the business's intrinsic value, stripping away market speculation and geopolitical risks.